Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W M Stadler

Showing results (31-40 of 70) with videos related to

Pageof 7
Sort By:
Cancer Chemotherapy and Pharmacology|August 13, 2002
A phase II trial of oral temozolomide in patients with metastatic renal cell cancerD K Park, C W Ryan, M E Dolan, et al.
Cancer|April 7, 1998
Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trialB I Rini, W M Stadler, R T Spielberger, et al.
Cancer|December 18, 2001
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignanciesS Mani, N J Vogelzang, D Bertucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2000
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium studyW M Stadler, N J Vogelzang, R Amato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2002
A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinomaC M George, N J Vogelzang, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2004
Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanomaM Aklilu, W M Stadler, M Markiewicz, et al.
Cancer Chemotherapy and Pharmacology|June 15, 2000
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrationsB C Goh, G F Fleming, L Janisch, et al.
Cancer Research|April 15, 1994
Homozygous deletions within chromosomal bands 9p21-22 in bladder cancerW M Stadler, J Sherman, S K Bohlander, et al.
Cancer Research|July 1, 1996
Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cellsC A Reznikoff, T R Yeager, C D Belair, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2000
Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancerB I Rini, N J Vogelzang, M C Dumas, et al.
Pageof 7

Showing results (31-40 of 70) with videos related to

Sort By:
Pageof 7
Cancer Chemotherapy and Pharmacology|August 13, 2002
A phase II trial of oral temozolomide in patients with metastatic renal cell cancerD K Park, C W Ryan, M E Dolan, et al.
Cancer|April 7, 1998
Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trialB I Rini, W M Stadler, R T Spielberger, et al.
Cancer|December 18, 2001
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignanciesS Mani, N J Vogelzang, D Bertucci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2000
Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II Consortium studyW M Stadler, N J Vogelzang, R Amato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2002
A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinomaC M George, N J Vogelzang, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2004
Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanomaM Aklilu, W M Stadler, M Markiewicz, et al.
Cancer Chemotherapy and Pharmacology|June 15, 2000
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrationsB C Goh, G F Fleming, L Janisch, et al.
Cancer Research|April 15, 1994
Homozygous deletions within chromosomal bands 9p21-22 in bladder cancerW M Stadler, J Sherman, S K Bohlander, et al.
Cancer Research|July 1, 1996
Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cellsC A Reznikoff, T R Yeager, C D Belair, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2000
Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancerB I Rini, N J Vogelzang, M C Dumas, et al.
Pageof 7